

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity	ABN/ARSN
<input type="text" value="Sigma Pharmaceuticals Limited"/>	<input type="text" value="15 088 417 403"/>

We (the entity) give ASX the following information.

Information about buy-back

1	Type of buy-back	<input type="text" value="On-market buy-back"/>
2	Date Appendix 3C was given to ASX	<input type="text" value="13 September 2012
(Associated Appendix 3D dated 2 October 2014)"/>

Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

	Before previous day	Previous day
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	<input type="text" value="98,267,210"/> <input type="text" value="182,699"/>
4	Total consideration paid or payable for the shares/units	<input type="text" value="\$70,731,313"/> <input type="text" value="\$152,316"/>

Appendix 3E
Daily share buy-back notice

	Before previous day	Previous day
5 If buy-back is an on-market buy-back	Highest price paid: \$0.8525 Lowest price paid: \$0.5600	Highest price paid: \$0.8400 Lowest price paid: \$0.8300 Highest price allowed under rule 7.33: \$0.8927

How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back	20,180,443
---	------------

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here:
 (Director/Company secretary)

Date: 20 April 2015

Print name: SUE MORGAN

=====
